Search results for "Epidermal necrolysis"

showing 2 items of 12 documents

Systemic therapies for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: a SCORTEN-based systematic review and meta-analysis.

2020

Background The SCORTEN score is a specific predictor of mortality for patients with Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN). There is little evidence in support of the common immunomodulating therapies for SJS/TEN. Objectives To systematically assess the effectiveness of several therapies for SJS/TEN through the SCORTEN score. Methods Databases were searched for original studies on the use of SCORTEN. Six meta-analyses were carried out on patients with SJS/TEN who received supportive care only or in combination with immunomodulating drugs: corticosteroids, cyclosporine, etanercept, immunoglobulins or a combination of corticosteroids with immunoglobulins. A multivaria…

medicine.medical_specialtybusiness.industryStevens johnsonRetrospective cohort studyDermatologymedicine.diseaseToxic epidermal necrolysisEtanerceptstomatognathic diseases030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineInfectious DiseasesAdrenal Cortex Hormones030220 oncology & carcinogenesisInternal medicineMeta-analysisStevens-Johnson SyndromeCyclosporineMedicineHumansbusinessmedicine.drugRetrospective StudiesJournal of the European Academy of Dermatology and Venereology : JEADVReferences
researchProduct

Levetiracetam‐induced pediatric toxic epidermal necrolysis successfully treated with etanercept

2020

Successful management of toxic epidermal necrolysis (TEN) with tumor necrosis factor-α inhibitors has been described in adults, but few cases have been reported in children. To date, only four pediatric cases of TEN treated with infliximab and one with etanercept have been published. We present the case of an 8-year-old boy diagnosed with TEN induced by levetiracetam, successfully treated with etanercept, systemic corticosteroids, and intravenous immunoglobulin.

musculoskeletal diseasesmedicine.medical_specialtybiologybusiness.industryDermatologymedicine.diseaseDermatologyToxic epidermal necrolysisInfliximabEtanercept030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesisPediatrics Perinatology and Child Healthbiology.proteinmedicineTumor necrosis factor alphaLevetiracetamAntibodyskin and connective tissue diseasesbusinessmedicine.drugPediatric Dermatology
researchProduct